CD274 and melanoma: We therefore assessed the efficacy of optimized SAProsome-3 in combination with PD-L1–based ICB in a syngeneic murine tumor model, an immunologically cold and poorly ICB-responsive tumor-B16F10 melanoma in C57BL/6 mice40.